reconstitution comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Lyophilised storage | −20 °C, dry, protected from light | Vials are sealed and allowed to reach room temperature before opening |
| Reconstituted storage | 2 to 8 °C, protected from light | Short-term holding; avoid repeated freeze-thaw cycles |
| Reconstitution solvent | Water for injection or bacteriostatic water | Added slowly along the vial wall to reduce foaming and shear |
| Purity measurement | RP-HPLC with area normalisation | Acetonitrile-water gradient monitored at roughly 214 nm |
| Identity confirmation | Electrospray ionisation mass spectrometry | Observed mass compared against the calculated peptide mass |
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
== Pathology == When the sulcular depth is chronically in excess of three millimeters, regular home care may be insufficient to properly cleanse the full depth of the sulcus, allowing food debris and microbes to accumulate, forming dental biofilm. This poses a danger to the periodontal ligament (PDL) fibers that attach the gingiva to the tooth. If accumulated microbes remain undisturbed in a sulcus for an extended period of time, they will penetrate and ultimately destroy the delicate soft tissue and periodontal attachment fibers. If left untreated, this process may lead to a deepening of the sulcus, recession, destruction of the periodontium, including the bony tooth socket, tooth mobility, and tooth loss. A periodontal pocket is a dental term indicating the presence of an abnormally deepened gingival sulcus.
=== Active laboratories === Northern Arizona University Amino Acid Geochronology Laboratory Archived 2017-03-31 at the Wayback Machine University of Massachusetts Amino Acid Geochronology Laboratory The University of Colorado Amino Acid Geochronology Lab University of Delaware Research Group University of York BioArCh Madrid School of Mines Biomolecular Stratigraphy Laboratory
=== GGQ motif === The GGQ motif is a conserved amino acid sequence in release factors through all domains of life. The GGQ site consists of two glycine amino acids followed by a glutamine. In eRF1, the GGQ site is on residues 183-185 of the polypeptide, which is located on Domain 2. The distant orientation of the GGQ site is stabilized by the hydrophobic effects of neighboring amino acid residues such as leucine 176, proline 177, phenylalanine 190, and leucine 193. The gln185 residue of the GGC motif is thought to be the main catalytic site for the hydrolysis of the peptidyl-tRNA ester bond in the peptidyl transferase of the ribosome. The GGQ site is not associated with any functions of stop codon recognition, ribosomal docking, or eRF3 binding.
Spectroscopy measures the interaction of the molecules with electromagnetic radiation. Spectroscopy consists of many different applications such as atomic absorption spectroscopy, atomic emission spectroscopy, ultraviolet-visible spectroscopy, X-ray fluorescence spectroscopy, infrared spectroscopy, Raman spectroscopy, nuclear magnetic resonance spectroscopy, photoemission spectroscopy, Mössbauer spectroscopy, and circular dichroism spectroscopy.
== Overview == Fructilactobacillus sanfranciscensis was first known to be isolated in 1971 by Kline and Sugihara. As lactic acid bacteria, the strains are Gram-positive, slender, rod-shaped, nonsporulating, and non-motile. They are also obligately heterofermentative, meaning that they can convert hexose sugars into not just lactic acid, but also ethanol, CO2, and/or acetic acid. This heterofermentative ability is key for this species' role in creating the unique flavor of sourdough bread. Sourdough starters are leavened by a mixture of yeast and lactobacilli in a ratio of about 1:100. Common yeast species found in combination with F. sanfranciscensis are Kazachstania humilis, Saccharomyces cerevisiae, and Wickerhamomyces anomalus. This yeast cannot metabolize the maltose found in the dough, while the Fructilactobacillus requires maltose. They therefore act without conflict for substrate, with lactobacilli utilizing maltose and the yeast utilizing the other sugars, including the glucose produced by the F. sanfranciscensis.
Sources: en.wikipedia.org
Blood pressure: First-line agents include thiazide-type diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers. Selection depends on comorbid conditions and tolerance. Dyslipidaemia: Statins remain first-line therapy for lowering low-density lipoprotein cholesterol (LDL-C). Fibrates or omega-3 fatty acids may be added for persistent severe hypertriglyceridaemia. Glucose control: Lifestyle intervention is the foundation of therapy. When medications are required, glucose-lowering agents with demonstrated cardiovascular and renal benefits—such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors—are preferred for individuals with type 2 diabetes or elevated cardiovascular risk. Obesity management: Pharmacotherapies such as semaglutide and tirzepatide produce clinically significant weight loss and improvements in blood pressure, lipids, and glycaemic control. Randomized controlled trials have reported reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
The history of penicillin traces how observations of antibiotic activity in the mould Penicillium led to the development of penicillins, a family of widely used antibiotics. Ancient societies used moulds to treat infections, and many people observed the inhibition of bacterial growth by moulds. While working at St Mary's Hospital in London in 1928, Scottish physician Alexander Fleming was the first to show experimentally that a Penicillium mould secretes an antibacterial substance, which he named "penicillin". The mould was found to be a variant of Penicillium chrysogenum (now called Penicillium rubens), a contaminant of a bacterial culture in his laboratory. The work on penicillin at St Mary's ended in 1929. In 1939, a team of scientists at the Sir William Dunn School of Pathology at the University of Oxford, led by Howard Florey, which included Edward Abraham, Ernst Chain, Mary Ethel Florey, Norman Heatley and Margaret Jennings, began researching penicillin. They developed a method for cultivating the mould and extracting, purifying and storing penicillin from it, together with an assay for measuring its purity. "Penicillin" now became the name of the active ingredient in the mould juice. They carried out experiments on animals to determine penicillin's safety and effectiveness before conducting clinical trials and field tests. They derived penicillin's chemical formula and determined how it works. The private sector and the United States Department of Agriculture located and produced new strains and developed mass production techniques.
Food chains are often used in ecological modeling (such as a three-species food chain). They are simplified abstractions of real food webs, but complex in their dynamics and mathematical implications. In its simplest form, the length of a chain is the number of links between a trophic consumer and the base of the web. The mean chain length of an entire web is the arithmetic average of the lengths of all chains in the food web. The food chain is an energy source diagram. The food chain begins with a producer, which is eaten by a primary consumer. The primary consumer may be eaten by a secondary consumer, which in turn may be consumed by a tertiary consumer. The tertiary consumers may sometimes become prey to the top predators known as the quaternary consumers. For example, a food chain might start with a green plant as the producer, which is eaten by a snail, the primary consumer. The snail might then be the prey of a secondary consumer such as a frog, which itself may be eaten by a tertiary consumer such as a snake which in turn may be consumed by an eagle. This simple view of a food chain with fixed trophic levels within a species: species A is eaten by species B, B is eaten by C, ... is often contrasted by the real situation in which the juveniles of a species belong to a lower trophic level than the adults, a situation more often seen in aquatic and amphibious environments, e.g., in insects and fishes. This complexity was denominated metaphoetesis by G. E. Hutchinson, 1959.
He returned in round 7, but had a subsequent dip in form. However, Essendon coach, Matthew Knights, persisted with Jetta and was paid back by his outstanding performance against Fremantle in round 14. The 2009 season was another important year in Jetta's development. A few quiet performances in the pre-season led to his omission from the side for the opening two rounds of the season. However, strong form for the Bendigo Bombers led to a recall for Essendon's vital round 3 encounter with Carlton. On 7 September 2014, Jetta parted ways with Essendon after eight seasons with the club. Jetta, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in February 2017; as a result, he served approximately seventeen months of his suspension and missed the entire 2016 WAFL season and parts of the 2015/16 and 2016/17 NTFL seasons. He later played with Peel Thunder in the WAFL and played for Pinjarra in the WA Amateur Football League in 2018.
When injected into the base of the penis, alprostadil may cause penile pain, dizziness, headache, high blood pressure, Peyronie disease, and burning at the injection site. When inserted into the urethra, alprostadil may cause urethral burning, penile pain, dizziness, headache, and urethral bleeding. When someone engages in vaginal sex after using an alprostadil urethral suppository, their partner may experience vaginal itching. Clinical trials for the treatment showed positive results in around 3,000 men that it was tested on; it is said to be usable by men with diabetes or heart problems and those who have undergone a prostatectomy.
Sources: en.wikipedia.org
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.
Liquid chromatography coupled to mass spectrometry is the most common approach because it combines a retention time with a mass measurement. A chromatographic peak alone cannot establish which peptide is present, so mass determination or amino acid analysis is used as an orthogonal confirmation alongside the separation.
This depends on buffer, pH, and concentration, and published stability data for this peptide are limited. In practice laboratories work through a refrigerated solution within a few weeks and discard samples that show cloudiness or visible particles. Freezing and thawing repeatedly is generally discouraged.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.